Biomedical

« Go back to Biomedical

Multi-Target Directed Drug for Alzheimer’s

The technology

Market need

Alzheimer’s disease (AD) is estimated to afflict 4 million people in the US. The current treatments are limited to symptomatic treatment of cognitive function. The main challenge in AD treatment is its apparent multi- factorial nature. This necessitates the progression from single-target drug development to multi-target.

Technology summary

The invention is a series of novel compounds that are useful for the treatment and prevention of Alzheimer’s disease. These compounds target multiple risk factors involved in AD including amyloid-β oligomers (AβO) oxidative stress and biometals and cell membrane/lipid rafts. The multifunctional Aβ oligomerization inhibitors (BMAOIs) strategy targeting CM/LR and other factors involved in the etiology of AD might be an ideal approach to overcome the limits of traditional single-target based approach.

Chart showing AD model and VCU drug reduces A beta OChart showing AD model and increasing concentration of VCU drug reduces oxidative stress

Technology status

Please see journal article- Lenhart et al. J. Med. Chem. 2010, 53, 6198–6209.

VCU Innovation Gateway is responsible for commercializing VCU research. We are commited to enhancing the overall culture of innovation and entrepreneurship at VCU and contributing to the growth of the region’s innovation ecosystem. This broader mission fosters collaborations with local and prospective companies to build external support for our inventors, and grows an entrepreneurial population to help us commercialize our technologies through new venture creation and thus support economic growth of our region.

VCU Innovation Gateway
Virginia Commonwealth University
800 E. Leigh St, Suite 3000
Box 980568
Richmond, VA 23298-0568

www.innovationgateway.vcu.edu
ott@vcu.edu
(804) 828-5188